Is it safe to use Kenalog (triamcinolone acetonide) on the face?

Use Kenalog on the Face with Extreme Caution and Only for Specific Indications

Kenalog (triamcinolone acetonide) should generally be avoided on facial skin due to the high risk of significant adverse effects including skin atrophy, telangiectasia, and striae, but can be used cautiously for intralesional injection of specific inflammatory lesions at very low concentrations.

Key Safety Concerns for Facial Use

The face is explicitly identified as highest risk for developing corticosteroid-related adverse effects 1. The 2021 AAD-NPF psoriasis guidelines specifically warn that "face and intertriginous areas, as well as chronically treated areas, especially forearms, are at greatest risk to develop these adverse effects" including skin atrophy, striae, folliculitis, telangiectasia, and purpura 1.

Why the Face is High-Risk

• Thinner skin with increased absorption of corticosteroids
• Greater vascularity leading to enhanced systemic absorption
• More visible cosmetic consequences of atrophy and telangiectasia
• Higher risk of exacerbating acne, rosacea, and perioral dermatitis 1

When Facial Use May Be Appropriate

Intralesional Injection for Inflammatory Acne

For individual inflammatory acne nodules on the face, intralesional triamcinolone can be used at concentrations of 2.5-10 mg/mL 2. The 2016 AAD acne guidelines recommend this as adjuvant therapy for larger papules or nodules, with the caveat to use lower concentrations and volumes to minimize adverse effects 2.

• Concentration: Most dermatologists use 2.5 mg/mL (52.5% in survey) for facial acne 3
• Volume: 0.05 mL is most common (42.3% of practitioners) 3
• Technique: Inject into the center of the lesion 3
• Timing: Flattens most nodules within 48-72 hours 2
• Adverse effects: Atrophy occurs in <1% of patients but can last >6 months when it does occur 3

The 2024 AAD acne guidelines updated this recommendation, emphasizing that intralesional corticosteroid injections should be used judiciously for patients at risk of scarring and/or for rapid improvement in inflammation and pain, specifically noting that "using a lower concentration and volume of corticosteroid can minimize the risks of local corticosteroid adverse events" 4.

Alternative Approach for Facial Inflammatory Conditions

For facial psoriasis or dermatitis, topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) are preferred over corticosteroids 1. These agents are specifically recommended for "thinner skin, such as facial and intertriginous areas" and serve as steroid-sparing agents for prolonged use (≥4 weeks) 1.

Critical Warnings

Periorbital Injections

Blindness from central retinal artery occlusion has been reported with periorbital injections, though not with low-pressure injections of triamcinolone acetonide at 2.5 mg/mL 5. Avoid periorbital use entirely unless absolutely necessary and with extreme caution.

Topical Application

There is no evidence supporting routine topical application of Kenalog suspension to facial skin. The FDA labeling for Kenalog-40 specifically states it is "suitable for intramuscular and intra-articular use only" and "not for intradermal injection" 6. Topical application would be off-label and carries the same atrophy risks as other potent corticosteroids.

Systemic Absorption Risk

Even with intralesional use, be aware that triamcinolone can cause systemic effects. The drug label warns about psychiatric derangements, elevated intraocular pressure, and HPA axis suppression 6. Facial injections may have enhanced systemic absorption due to increased vascularity.

Practical Algorithm for Facial Corticosteroid Decision-Making

1. First-line: Use topical calcineurin inhibitors for inflammatory facial conditions requiring prolonged treatment
2. For isolated inflammatory acne nodules: Consider intralesional triamcinolone 2.5 mg/mL, 0.05 mL maximum per lesion
3. For facial psoriasis plaques: Avoid corticosteroids; use calcineurin inhibitors or other steroid-sparing agents
4. Never use: High-potency topical corticosteroids (Class 1-3) on facial skin
5. If corticosteroid absolutely necessary: Use lowest potency (Class 6-7) for shortest duration possible (<4 weeks)

Common Pitfalls to Avoid

• Using concentrations >10 mg/mL on facial skin increases atrophy risk dramatically
• Repeated injections in the same site compound atrophy risk
• Failing to counsel patients about hypopigmentation and atrophy risks before injection (50.5% of dermatologists counsel before every injection) 3
• Assuming atrophy is temporary: When it occurs, it typically lasts >6 months 3
• Using for conditions that worsen with steroids: Acne rosacea, perioral dermatitis, and tinea infections can all be exacerbated 1